Publications — John Paul Runyon

PUBLICATIONS BY JOHN PAUL RUNYON, MD.

AKA, RUNYON JP, AKA, RUNYON J

 

The following are publications that Dr. John Paul Runyon has authored or co-authored.  Listed in descending order of time, meaning the most recent ones are post first.

Laird J, Joye J, Sachdev N. Huang P, Caputo R, Mohiuddin I, Runyon J, Das T. Recanalization of Infrainguinal Chronic Total Occlusions With the Crosser System: Results of the PATRIOT Trial. J Invasive Cardiol. 2014 Oct;26(10), 497-8.Losordo DW, Kibbe MR, Mendelsohn R, Marston W, Driver VR, Sharafuddin M, Teodorescu V, Weichmann BN, Thompson C, Kraiss L, Carman T, Dohad S, Huang P, Junge CE, Story K, Weistroffer T, Thorne TM, Millay M, Runyon JP, Schainfeld R. Autologous CD34+ cell therapy for critical limb ischemia investigators. Circ Cardiovasc Interv. 2012 Dec; 5(6):821-30.

Safain RD, Niazi K, Runyon JP, Dulas D, Weinstock B, Ramaiah V, Heuser R. Orbital atherectomy for infrapopliteal disease: Disease concept and outcome data for the OASIS trial. Catheter Cardiovasc Interv. 2009 Feb 15;73(3); 406-12.

Runyon JP, “Plaque excision and stent graph deployment for SFA occlusion: A case report on this combination therapy.” Endovascular Today. 2007, February; 90-2.

McKinsey JF, MD, Ramaiah VG, MD, Runyon JP, MD, Allie DE, MD, Walker CM, MD, Garcia L, MD, Gammon RS, MD: 1 Year Results of Treatment of Infrapopliteal Arterial Occlusive Disease using the SilverHawk Plaque Excision Device. Submitted September 2005 to The Peripheral Vascular Surgery Society, for the PVSS Meeting January 27-29, 2006. Accepted.

Ramaiah V, Gammon R, Kiesz S, Cardenas J, Ruyon JP, Fail P, Walker C, Allie DE, Chamberlin J., Solis M, Garcia L, Kandzari D. Midterm outcomes from the TALON Registry: Treating peripherals with SilverHawk: outcomes collection. J Endovas Ther. 2006 Oct; 13(5): 592-602.

Maurice Solis, Stefan Kiesz, Roger Gammon, Venkatesh Ramaiah, Craig Walker, David Allie, John Runyon, Joseph Cardenas: Early Results of Plaque Excision in the Treatment of Lower Extremity In- Stent Restenosis. Accepted TCT05 Washington Convention Center, Washington DC, October 16-21, 2005.

Roger Gammon Joseph Cardenas, Venkatesh Ramaiah, John Runyon, Peter Fail, Craig Walker, David Allie, Jack Chamberlin, Maurice Solis, Lawrence Garcia, Prakash Makam, Jose Vale, Stefan Kiesz. Acute and Long-Term Outcomes for Treatment of Lower Extremity PAD with SilverHawk Plaque Excision System. Accepted. TCT05 Washington Convention Center, Washington DC, October 16-21, 2005.

Young JJ, Marcus DP, Abbotsmith CW, Broderick TM, Choo JK, Runyon JP, Schneider JR, Shimshak TM, Geier RP, Keriakes DJ. “Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice.” J Invasive Cardiol. 2003 Jan:15 Suppl A:9A-13A.

Gilchrist IC, O’Shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, Kleiman NS, Talley D, Aguirre F, Davidson C, Runyon J, Tcheng JE. “Pharmacodynamics and pharmacokinetics of higher-dose, double- bolus eptifibatide in percutaneous coronary intervention.” Circulation. 2001 Jul 24;104(4):406-11.

Kandzari DE, Behar VS, Skektch MH Jr., Keriakes DJ, Shimshak T, Broderick T, Young J, Runyon JP, Safian RD, Kern M, Colombo A. “Extensive thrombus prior to elective percutaneous coronary intervention.” J Invasive Cardiol. 2001 Jul:13(7):538-42.

Keriakes DJ, Young JJ, Runyon JP, Shimshak TM. “Ticlopidine monotherapy following coronary stent deployment: penny wise and pound foolish.” J Invasive Cardiol. 2001 Jun;13(16):437-8.

Dippel EJ, Keriakes DJ, Tramuta DA, Broderick TM, Shimshak TM, Roth EM, Hattemer CR, Runyon, JP, Whang DD, Schneider JR, Abbottsmith, CW. “Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIB/IIIa blockade: an algorithm for percutaneous management.”Catheter Cardiovasc Interv. 2001 Mar;52(3):279-86.

Runyon, JP, Snavely DD. “Rapid dissolution of intracoronary thrombus with eptifibatide therapy in a patient with post-infarction angina.” J Invasiv Cardiol. 2000 Dec; 12 Suppl D4D-7D.

Keriakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CR, Roth EM, Whang DD, Cocks D, Abbottsmith CW. “Abciximab provides cost-effective survival advantage in high-volume interventional practice.” Am Heart J. 2000 Oct;140(4):603-10.

Keriakes, DJ, Runyon JP, Broderick TM, Shimshak TM. “IIb’s are not IIb’s.” Am J Cardiol. 2000 Apr 27;85(8A):23C-31C.

Runyon, JP. “Facilitated percutaneous coronary intervention: validating the open artery hypothesis.” J Invasive Cardiol. 2000 Mar; 12 Suppl B:22B-25B.

Keriakes DJ, Broderick TM, Roth EM, Whang D, Shimshak T, Runyon JP, Hattemer C, Schneider J, Lacock P, Muyeller M, Abbottsmith, CW. “Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.”Am J Cardiol. 1999 Aug 15;84(4):391-5.

Keriakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Drelling RJ, Hantsbarger GL, Bryzinski B, Rtopoll EJ. “Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIB/IIIa receptor blockade with oral Xemilofiban: Results of a multicenter, placebo-controlled, randomized trial.” Circulation. 1998 Sept. 29:98(13):1268-78.

Keriakes DJ, Kleiman N., Ferguson JJ, Runyon JP, Roderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ. “Sustained platelet glycoprotein IIb/IIIa blockade with oral Xemilofibal in 111 patients after coronary stent deployment.” Circulation. 1997 Aug 19:96(4): 1117-21.

Keriakes DJ, Kleiman N, Ferguson JJ, Runyon JP, et al: Sustained Platelet Glycoprotein IlB/IIIa Blockade with Oral Xemilofiban in 170 Patients After Coronary Stent Deployment. Circulation. 1997: Aug; 96(4):1117.

Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP: Abciximab-Associated Profound Thrombocytopenia: Therapy with Immunoglobulin and Platelet Transfusion. American Journal of Cardiology. 1996: Nov; 78:1161-1163.

Runyon, JP, et al. “Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion.” Am J Cardiol. 1996 Nov. 15;78(10):1161-3.

Keriakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ. “Differential dose-response to oral Xemilofiban after antecedent intravenous Aciximab administration for complex coronary intervention.” Circulation. 1996 Sept. 1;94(5)906-10.

Kereiakes DJ, Runyon JP, et al. “Differential Dose-Response to Oral Xemilofiban After Antecedent Intravenous Abciximab.” Circulation. 1996: Sept 1; 94(5):906-910.

Gibler WB, Runyon JP, Levy RC, Sayre MR, Kacich, R, Hattemer CR, Hamilton C, Gerlach JW, Walsh RA. “A rapid diagnostic and treatment center in the emergency department for patients with chest pain.” Ann Emerg Med. 1995 Jan;25(1):1-8.

Gibler WB, Sayre MR, Levy RC, Runyon JP, Kacich R., Hamilton C, Walsh RA. “Serial 12-lead electrocardiographic monitoring in patients presenting to the emergency department with chest pain.” J Electrocardiol. 1993:26 (Suppl):238-43.

Gibler WB, WalshRA, LevyRC, RunyonJP.“Rapid Diagnostic and Treatment Center in the Emergency Department for Patients with Chest Pain.” Submitted, American Heart Association, 65th Scientific Sessions, November, 1992.

Gibler WB, Runyon JP, Levy RC, Sayre MR, Kacich, R, Hattemer CR, Hamilton C, Gerlach JW, Walsh RA. “A rapid diagnostic and treatment center in the emergency department for patients with chest pain.” Circulation. 86(4):56, 1992.

Runyon JP, Gerson MC: “Noninvasive Test Selection in the Coronary Care Unit,” in Cardiac Nuclear Medicine, 2nd ed., edited by Myron C. Gerson. McGraw Hill, New York, 1991, pp. 337-386.